All In Biotech

Drug Trial Radar · NCT06593522

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

61

Actual

Start

Dec 26, 2024

Primary completion

Oct 31, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).

Conditions

  • MTAP-deleted NSCLC

Interventions

  • anvumetostatDrug

    Film-coated tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response (OR) per RECIST 1.1Time frame: Up to 35 months
  2. Objective response (OR) Measured by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) and Assessed per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)Time frame: Up to 35 months
  3. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 35 months
  4. Number of Participants Experiencing Events of Interest (EOIs)Time frame: Up to 35 months
  5. Maximum Concentration (Cmax) of anvumetostatTime frame: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose
  6. Time to Cmax (Tmax) of anvumetostatTime frame: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose
  7. Area Under The Concentration-time Curve (AUC) of anvumetostatTime frame: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose

Locations

91 sites in 16 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • City of Hope Orange County Lennar Foundation Cancer Center

    Duarte, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut

  • Hartford HealthCare Cancer Institute - Manchester

    Plainville, Connecticut

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Our Lady of the Lake Cancer Institute

    Baton Rouge, Louisiana

  • Trinity Health Saint Joseph Mercy Ann Arbor

    Ann Arbor, Michigan

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Sarah Cannon Research Institute Oncology Partners

    Nashville, Tennessee

  • United States Oncology Regulatory Affairs Corporate Office

    Nashville, Tennessee

  • Texas Oncology Central/South Texas

    Austin, Texas

  • Sarah Cannon Research Institute

    Dallas, Texas

  • Texas Oncology - Dallas Fort Worth

    Dallas, Texas

  • US Oncology Research Investigational Products Center

    Irving, Texas

  • Texas Oncology Northeast Texas

    Tyler, Texas

  • Virginia Cancer Specialists PC

    Fairfax, Virginia

  • GenesisCare -North Shore Oncology

    St Leonards, New South Wales, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, New South Wales, Australia

  • Mater Hospital Brisbane

    South Brisbane, Queensland, Australia

  • Cancer Research South Australia

    Adelaide, South Australia, Australia

  • Instituto de Educacao Pesquisa e Gestao em Saude

    Rio de Janeiro, Brazil

  • Centro Paulista de Oncologia

    São Paulo, Brazil

  • Núcleo de Oncologia da Bahia

    Salvador, Estado de Bahia, Brazil

  • Liga Norte-Riograndense Contra O Cancer

    Natal, Rio Grande do Norte, Brazil

  • Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundacao pio xII Barretos

    Barretos, São Paulo, Brazil

  • Fund Faculdade Regional Med Sao Jose Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Instituto do Cancer Estado SP Icesp

    São Paulo, São Paulo, Brazil

  • Fundacao Antonio Prudente - Hosp AC Camargo

    São Paulo, São Paulo, Brazil

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • William Osler Health System - Brampton Civic Hospital

    Brampton, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • McGill University Health Centre Glen Site

    Montreal, Quebec, Canada

  • Beijing Cancer Hospital

    Beijing, China

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.